Niaspan Reverse Payment Antitrust Litigation

Court: United States District Court, Eastern District of Pennsylvania

Case No.: 13-md-2460

Leadership Position: Interim Co-Lead Counsel

WBE is Interim Co-Lead Counsel for the end purchaser plaintiffs in an antitrust class action against AbbVie Inc. and Teva Pharmaceuticals USA, Inc. (and related companies) involving the cholesterol drug Niaspan.  The plaintiffs allege that the defendants conspired to keep a generic version of Niaspan off the market for more than eight years.  The plaintiffs have also alleged that the defendants’ conduct caused consumers and drug benefit plans to pay more for Niaspan and its generic equivalents than they otherwise would have, in violation of state antitrust and consumer protection laws.

To view a copy of the consolidated class action complaint, click here.

News Articles

Lawsuit Accuses Meta of Using Facebook and Instagram Images to Build Facial Recognition and Generative AI Systems Without Consent

CHICAGO, Sept. 4, 2026 — A class action lawsuit filed Friday, September 4, 2026, in the U.S. District Court for the Northern District of Illinois, Eastern Division, accuses Meta Platforms Inc. ...

Managing Partner Kenneth A. Wexler Recognized by Best Lawyers

  We are pleased to share that founder and Managing Partner, Kenneth A. Wexler, has been recognized in the 2027 edition of Best Lawyers for his work in Antitrust Law. Best Lawyers ...

College Athletes Challenge NCAA’s New Age-Based Eligibility Rules in Federal Antitrust Lawsuit

Plaintiffs allege the NCAA’s new eligibility system arbitrarily limits athletes’ ability to compete, earn name and likeness compensation, and access revenue-sharing opportunities. On Monday, ...
No results found.